Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gadobenate dimeglumine

Next Previous
X
Search
Drug Profile

Gadobenate dimeglumine

Alternative Names: B-19036; B-19036/7; E 7155; Gadobenic acid; Gd-BOPTA/Dimeg; MultiHance

Latest Information Update: 25 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bracco Diagnostics
  • Class Diagnostic agents; Gadolinium-containing contrast agents; Hexosamines; Organometallic compounds; Small molecules; Sugar alcohols
  • Mechanism of Action Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Arterial occlusive disorders; CNS disorders

Most Recent Events

  • 30 Jan 2018 The label for gadobenate dimeglumine contains a black box warning for nephrogenic systemic fibrosis
  • 30 Jan 2018 The US Food and Drug Administration approves gadobenate dimeglumine for CNS disorders (Diagnosis, In neonates, In infants) in USA
  • 10 Mar 2017 EMA's Pharmacovigilance Risk Assessment Committee recommends suspension of gadobenate dimeglumine from the market in the European Union

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top